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This is an
(https://creat
purposes, prA simple and convenient reversed-phase high-performance liquid chromatography (RP-HPLC) method for simultaneous
separation, identification, and determination of sodium metabisulfite and sodium benzoate in pharmaceutical formula-
tion has been developed and validated. Chromatographic separation was achieved on RP column Zorbax Extend C-18
(150 × 4.6 mm i.d., 3.5 μm particles), and mixture of 0.1% phosphoric acid and acetonitrile in the ratio 62:38 (v/v) was
used as a mobile phase. The flow rate was set at 1.0 mL/min with detection wavelength of 275 nm. The method was
successfully validated according to International Conference on Harmonization (ICH) guidelines acceptance criteria.
The method is selective, as no interferences were observed at retention times corresponding to these analytes. Results
of regression analyses (r) and statistical insignificance of calibration curve intercepts (p) proved linearity of the method
in defined concentration ranges for sodium metabisulfite and sodium benzoate (0.05–0.15 mg/mL). Relative standard
deviations calculated for both analytes in precision testing were below the limits defined for active pharmaceutical in-
gredients (analysis repeatability: <2%; intermediate precision: <3%). Recovery values were between 98.16% and
101.94%. According to results of robustness testing, chromatographic parameters are not significantly influenced by
small variation of acetonitrile content in mobile phase, column temperature, and flow rate. Finally, the method was ap-
plied for quantitative determination of investigated preservatives in real sample analysis.
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The analysis of preservatives in commercial pharmaceutical
products is particularly important for both quality assurance and
consumer protection. International Conference on Harmonization
(ICH) guidance recommends that the finished product shelf-life
specification should also include preservative content and limits
for antimicrobial preservative present [1].
The antioxidants are substances with lower oxidation potential
compared to that of active substances they protect. Sulfureous
compounds are largely used as antioxidants in food products.
Some sulfitic species, especially sodium metabisulfite, have been
used in pharmaceutical formulations. Sodium metabisulfite is
used as an antioxidant in oral, parenteral, and topical pharmaceu-
tical formulations, at concentrations of 0.01–1.0% w/v. Primarily,
sodium metabisulfite is used in acidic preparations, where it un-
dergoes an instantaneous hydrolysis to sodium bisulfite and fur-
ther to a weak sulfurous acid. Sodium metabisulfite also has
some antimicrobial activity, which is greatest at acid pH, and
may be used as a preservative in oral preparations such as syrups
[2]. A necessity for a strict control of sodium metabisulfite usage
results from its adverse effect on health cytotoxicity and mutage-
nicity of this compound is confirmed [3–6].
Up to date, different analytical methods have been reported for
determination of sodium metabisulfite based on high-performance
liquid chromatography (HPLC) [7], ion chromatography with sup-
pressed conductivity detection [8, 9], flow injection coulometry
[10], amperometric method [11], capillary zone electrophoresis
with indirect detection [12], and isotachophoretic method [13].
Sodium benzoate is generally used as a chemical preservative
to prevent alteration or degradation caused by microorganisms.correspondence: ocudina@pharmacy.bg.ac.rs
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ovided the original author and source are credited, a link to theIn acidic media (pH 2–5), sodium benzoate exhibits inhibitory
activity against a wide range of fungi, yeasts, molds, and bacteria
and is widely used in variety of products, such as cosmetics and
pharmaceuticals, but more commonly in foods. It is used in con-
centrations of 0.02–0.5% in oral medicines, 0.5% in parenteral
products, and 0.1–0.5% in cosmetics [2].
Its toxicity is generally low owing to fast hydrolysis in vivo to
parent acid, which is rapidly conjugated and excreted [2]. How-
ever, excessive intake of preservatives might be potentially harm-
ful to the consumers [14].
Most of the literature data concerns determination of sodium
benzoate in a mixture with drugs or other preservatives. Preserva-
tives are most commonly determined in samples of food and bev-
erage [15–18], pharmaceuticals [19–22], and cosmetics [23, 24].
The most frequently used technique in preservative analysis is
HPLC. The literature also contains other analytical techniques for
determination of sodium benzoate such as ultraviolet (UV) spec-
troscopy [25], near-infrared reflectance spectroscopy [26], chiral
ligand exchange capillary electrophoresis [27], fluorescence polar-
ization immunoassay [28], and electrochemistry using ion-selec-
tive electrodes [29].
To our knowledge, there is no report about simultaneous deter-
mination of sodium metabisulfite and sodium benzoate in phar-
maceutical products. The aim of this work was to develop fast,
simple, selective, and easy-to-use method for simultaneous con-
trol of those two preservatives in pharmaceuticals.Experimental Part
Chemicals and Reagents. HPLC gradient grade acetonitrile
was purchased from JT Baker (Phillipsburg, NJ, USA) and
orthophosphoric acid from Merck (Darmstadt, Germany).Acta Chromatographica 31(2019)2, 133–137
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HPLC Method for Determination of PreservativesWorking standards of sodium metabisulfite (99.56%) and sodium
benzoate (99.43%) were produced by Centrohem (Stara Pazova,
Serbia). KlozanW placebo contains ethylenediaminetetraacetic
acid (EDTA) disodium salt, trisodium citrate dihydrate, citric acid
monohydrate, propylene glycol, and glycerol anhydrous.
KlozanW suspension for injection was produced by Evrolek-
Pharmacija d.o.o. (Šabac, Serbia).
Chromatographic Conditions. HPLC analysis was
performed on chromatograph Dionex UltiMate 3000 system
(Thermo Fisher Scientific, Germering, Germany) equipped with
quaternary pump, autosampler, and DAD detector. Intermediate
precision was tested on chromatograph Agilent 1200 (Agilent
Technologies, Palo Alto, CA, USA) equipped with binary pump,
manual injector (20 μL loop), and DAD detector. The column
used was Zorbax Extend (150 × 4.6 mm i.d., 3.5 μm particles),
thermostated at 25 °C. Mobile phase consisted of 0.1%
phosphoric acid and acetonitrile (62:38 v/v). The flow rate was
1 mL/min, and detection was performed at 275 nm.
Preparation of Solution
Solvent. One milliliter of ortophosphoric acid 85% was trans-
ferred to 1000 mL volumetric flask and diluted with deionized
water.
Placebo Stock Solution Spiked with Active Pharmaceutical
Ingredients. An accurately weighed amount of citric acid
(70 mg), sodium citrate dihydrate (47 mg), EDTA disodium salt
(10 mg), levamisole hydrochloride (500 mg), glycerol anhydrous
(430 mg), and propylene glycol (6.15 mg) was transferred to
10 mL volumetric flask containing 2.3 mL of water for injec-
tion. Every additional substance was transferred to a volumetric
flask only after dissolving the previous one. Finally, accurately
weighed amount of closantel (500 mg) was added and the mix-
ture was sonicated for 15–20 min. Prepared and sonicated solu-
tion was centrifuged and filtered through polytetrafluoroethylene
(PTFE) membrane filter (0.45 μm). One milliliter of supernatant
solution was transferred to a 10 mL volumetric flask and diluted
with the solvent.
Placebo Working Solution. One milliliter of placebo stock
solution was transferred to 10 mL volumetric flask and diluted
with the solvent.
Standard Stock Solution. An accurately weighed amount of
sodium metabisulfite (10 mg) and sodium benzoate (10 mg) were
transferred to 10 mL volumetric flask, and 7 mL of solvent was
added, sonicated for 5–10 min, diluted with the solvent, and fil-
tered through PTFE membrane filter (0.45 μm).
Standard Working Solution. One milliliter of standard stock
solution was transferred to a 10 mL volumetric flask and diluted
with the solvent.
Placebo Solution Spiked with Standard Solution of Sodium
Metabisulfite and Sodium Benzoate. One milliliter of standard
stock solution and 1 mL of placebo working solution were trans-
ferred to a 10 mL volumetric flask and diluted with the solvent.
Method Validation. The performance and validation of the
method were evaluated considering the guidelines of the ICH
[30] by determining selectivity, linearity, precision, accuracy, and
robustness.
Selectivity. Selectivity testing of this method was performed
by injecting three solutions under optimal chromatographic con-
ditions: KlozanW placebo solution, KlozanW placebo solution
spiked with standard solution of sodium metabisulfite and so-
dium benzoate, and working standard solution of tested sub-
stances. Selectivity was tested by examining the chromatogram
of KlozanW placebo at retention times corresponding to sodium
metabisulfite and sodium benzoate.
Linearity. For the construction of calibration curves, five solu-
tions of mixture of analytes (sodium metabisulfite and sodium
benzoate) were prepared by diluting stock standard solution with
the solvent. Linearity for both compounds was tested in the range134of 0.05–0.15 mg/mL. Each point of the calibration graph corre-
sponded to the mean value obtained from three independent
measurements.
Precision. Precision was assessed in terms of repeatability
and intermediate precision. Six solutions of the mixture of ana-
lytes at 100% of the test concentration (0.1 mg/mL) were pre-
pared for analysis repeatability and injected, and relative standard
deviation was calculated. For intermediate precision, six solutions
were prepared as described for analysis repeatability and this test
was performed by another analyst, another day, on another
HPLC chromatograph and with different set of reagents.
Accuracy. Accuracy was tested at three concentration levels
(80%, 100%, and 120%) by adding three different volumes of
stock standard solution (800, 1000, and 1200 μL) into three
10 mL volumetric flasks, each containing previously measured
1 mL of placebo stock solution and 4 mL of the solvent. The so-
lutions were diluted, filtered, and injected. Concentrations of so-
dium metabisulfite, as well as sodium benzoate were 0.08 mg/mL
(80%), 0.1 mg/mL (100%) and 0.12 mg/mL (120%).
Robustness. Robustness was tested by small variations of se-
lected parameters: acetonitrile content in mobile phase, column
temperature, and flow rate. Working standard solution was pre-
pared by diluting stock standard solution with the solvent to ob-
tain concentration of 0.1 mg/mL for both analytes. Placebo
solution spiked with standard solution of sodium metabisulfite
and sodium benzoate was prepared by adding 1 mL of stock
standard solution and 1 mL of placebo stock solution into 10 mL
volumetric flask and diluting with the solvent. Working standard
solution and placebo solution spiked with standard solution of so-
dium metabisulfite and sodium benzoate were injected under
each of tested chromatographic conditions, and peak areas of
tested analytes were monitored.
Real Sample Testing. Five milliliters of KlozanW suspension
for injection was centifuged (5 min on 4000 rpm), and
supernatant liquid was filtered through PTFE membrane filter
(0.45 μm). One milliliter of obtained filtrate was transferred to
10 mL volumetric flask, diluted with the solvent, and injected.
Results and Discussion
Method Development and Optimization. Optimum
conditions, which are necessary for the quantitative analysis of
compounds with maximum sensitivity, were established by
selection of stationary phase, varying mobile phase composition
and pH of the mixed solvent system, and observing their effects
on capacity factor (k), peak width, and symmetry. Acetonitrile is
selected as organic solvent because of higher elution strength.
In order to study the effect of mobile phase pH on
chromatographic separation, the effect of pH on the retention
time of each analyte was investigated over the range of 2.0–6.0.
The results obtained showed that the resolution of sodium
metabisulfite decreases as the pH increases which can be
explained with the fact that sodium metabisulfite exsists in
anionic form in acidic medium [31]. Therefore, a pH 3.0 was
selected for further investigation. The 1.0 mL/min flow rate was
selected to achieve the separation of peaks. It was found that
ambient temperature is an appropriate temperature with respect
to peak separation and shape. Based on the UV spectra of
sodium metabisulfite and sodium benzoate, 275 nm was found
to be appropriate wavelength for the determination of those two
preservatives. From the mobile phase selection study, the
optimized HPLC parameters were as follows: flow rate,
1.0 mL/min; column temperature, 25 °C; and isocratic program
with a mixture of 0.1% phosphoric acid and acetonitrile in the
ratio of 62:38 (v/v) as a mobile phase. The chromatographic
separation was performed on various columns including RP8,
RP18, cyano, and amino HPLC columns. Retention time was
Table 1. Linearity parameters of the proposed method
Sodium metabisulfite Sodium benzoate
Range (mg/mL) 0.051–0.165 0.052–0.157
a 54.7587 110.9967
b −0.2883 −0.2127
r 0.9995 0.9999
p 0.09703 0.283904
SE intercept 0.120795 0.14539
SE slope 1.041905 1.312963
a, slope; b, intercept; r, correlation coefficient; p, statistical significance
of calibration curve intercept (p > 0.05); SE intercept, standard error of
intercept; and SE slope, standard error of slope.
B. Ivković et al.not affected in the case of sodium metabisulfite, while k for
sodium benzoate increased with increasing polarity of stationary
phase. Therefore, RP18 column was selected in order to achieve
high resolution between peaks of analyzed analytes.
Method Validation
Selectivity. The method is selective for simultaneous deter-
mination of sodium metabisulfite and sodium benzoate, as no
interferences were observed at retention times corresponding
to these analytes (Figure 1).
Linearity. Results of regression analyses (r = 0.9995 for so-
dium metabisulfite and r = 0.9999 for sodium benzoate) as
well as statistical insignificance of calibration curve intercepts
(p > 0.05) proved linearity of the method in defined concen-
tration ranges (Table 1).Figure 1. Chromatograms: a) KlozanW placebo solution; b) KlozanW placebo s
and sodium benzoate (tr = 3.024) and c) standard solution of sodium metabisulfiPrecision. Precision was tested at concentration level of
100%. Relative standard deviations calculated for sodiumolution spiked with standard solution of sodium metabisulfite (tr = 1.766)
te and sodium benzoate
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HPLC Method for Determination of Preservativesmetabisulfite and sodium benzoate were below the limits defined
for active pharmaceutical ingredients (analysis repeatability:
<2%; intermediate precision: <3%) [27]. The results of precision
testing are presented in Table 2.
Accuracy. Recovery for sodium metabisulfite and sodium
benzoate was tested at three levels (80%, 100%, and 120%) inTable 2. Results of precision and accuracy testing
Sodium metabisulfite Sodium benzoate
Precision
Analysis repeatability
Concentration of analyte (mg/mL) 0.0980 0.1015
Mean value (mg/mL) 0.0954 0.1024
Standard deviation (mg/mL) 0.001 0.0004
RSD (%) 1.03 0.43
Intermediate precision
Concentration of analyte (mg/mL) 0.0940 0.1015
Mean value (mg/mL) 0.0926 0.1016
Standard deviation (mg/mL) 0.001 0.002
RSD (%) 1.37 1.64
Accuracy
Concentration 1 (mg/mL) 98.16 101.52
Recovery (%)
Concentration 2 (mg/mL) 98.84 99.90
Recovery (%)
Concentration 3 (mg/mL) 99.06 101.94
Recovery (%)
Concentration 1, 80%; concentration 2, 100%; and concentration 3, 120%.
Table 3. Results of robustness testing
Optimal chromatograp
Mobile phase: 0.1% phosphoric acid–CH3CN, 62:38 (v/v)
Flow rate: 1.0 mL/min
Column temperature: 25 °C
Sodium m
Cs (mg/mL)
0.098
Variation Sodium m
Cs (mg/mL)
Acetonitrile content 34 0.098
Deviation (%) 0
42 0.098
Deviation (%) 1
Variation Sodium m
Cs (mg/mL)
Flow rate 0.9 0.098
Deviation (%) 0
1.1 0.098
Deviation (%) 0
Variation Sodium m
Cs (mg/mL)
Column temperature 22.5 0.098
Deviation (%) 1
27.5 0.098
Deviation (%) 0
Figure 2. Chromatograms of KlozanW solution
136regard to the concentration in solution prepared for the determi-
nation of analytes. These values were between 98.16% and
101.94%, which is within the required range for active pharma-
ceutical ingredients (98–102%) [32]. These results (Table 2)
proved the method's accuracy for the simultaneous determination
of sodium metabisulfite and sodium benzoate.
Robustness. The robustness of an analytical procedure is a
measure of its capacity to remain unaffected by small, but delib-
erate variations in method parameters provide an indication of its
reliability during normal usage. Robustness was tested by small
variations of selected parameters: acetonitrile content in mobile
phase, column temperature, and flow rate. Standard working so-
lution and placebo solution spiked with standard solution of so-
dium metabisulfite and sodium benzoate were injected according
to chromatographic conditions presented in Table 3. The concen-
tration of analyzed analyte was calculated according to Eq. (1).
C0 ¼ Ai=ASð Þ  CSð1Þ
Ai — peak area of analyzed compound in placebo solution
spiked with standard solution of sodium metabisulfite and so-
dium benzoate
AS — peak area of analyzed compound in standard working
solution
(1)hic conditions
etabisulfite Sodium benzoate
Co (mg/mL) Cs (mg/mL) Co (mg/mL)
0.0954 0.1015 0.1024
etabisulfite Sodium benzoate
Co (mg/mL) Cs (mg/mL) Co (mg/mL)
0.0958 0.1015 0.1017
.41 0.69
0.0969 0.1015 0.1020
.94 0.40
etabisulfite Sodium benzoate
Co (mg/mL) Cs (mg/mL) Co (mg/mL)
0.0959 0.1015 0.1027
.92 0.30
0.0951 0.1015 0.1020
.10 0.40
etabisulfite Sodium benzoate
Co (mg/mL) Cs (mg/mL) Co (mg/mL)
0.0961 0.1015 0.1026
.12 0.19
0.0952 0.1015 0.1028
.20 0.39
B. Ivković et al.CS — concentration of analyzed compound in standard work-
ing solution (mg/mL)
C0 — concentration of analyzed compound in placebo solu-
tion spiked with standard solution of sodium metabisulfite and
sodium benzoate
The results of robustness testing are presented in Table 3.
According to these results, it can be concluded that tested chro-
matographic parameters are not significantly influenced by se-
lected factors because the obtained deviations were below the
limit defined for precision of the method (±3%). Thus, robust-
ness of developed method was confirmed.
Analysis of Pharmaceutical Dosage Form. Applicability in
routine of this method was tested by analysis of KlozanW
suspension for injection. The content of sodium metabisulfite
was 95% (0.095 mg/mL) while the content of sodium
benzoate was 103% (0.103 mg/mL). These results are in
accordance with KlozanW suspension for injection specifi-
cation. Chromatograms of KlozanW solution are presented in
Figure 2.
Conclusion
The newly developed reversed-phase RP-HPLC method
was found to be convenient for the simultaneous determina-
tion of sodium metabisulfite and sodium benzoate. The
method provides selective quantification of those two preser-
vatives within 3 min without interference from ingredient and
placebo. Obtained validation parameters (selectivity, linearity,
precision, accuracy and robustness) proved that the suggested
method is convenient enough for routine determination of so-
dium metabisulfite and sodium benzoate in quality control
laboratories.
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